parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in platelets	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 397	0.79
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9229

receipt 9237: INF2 in dopamine neurons, braak

power: full sample -0.41 (p 0.089, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.50 (p 0.036, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.040, n 18). not the mix.
skeptic: leave-one-out range -0.51 to -0.34, sign flips 0; without severely affected donors -0.41 (p 0.089, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for INF2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9236: INF2 in oligodendrocytes, braak

power: full sample -0.48 (p 0.044, n 18), 95% CI -0.77 to -0.02. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.53 (p 0.025, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.53 (p 0.025, n 18). not the mix.
skeptic: leave-one-out range -0.57 to -0.41, sign flips 0; without severely affected donors -0.48 (p 0.044, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for INF2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts